Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety

Clin Exp Rheumatol. 2011 May-Jun;29(3 Suppl 66):S15-27. Epub 2011 Aug 29.

Abstract

Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific recommendations in order to assist rheumatologists in prescribing these drugs. The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) decided to update its recommendations, and, to this end, a systematic literature review was performed and the evidence derived from it was discussed and summarized as expert opinions. Levels of evidence and strength of recommendations were reported. The recommendations reported refer to the safety of biologic agents and are intended to help prescribing rheumatologists to optimise the use of biologic agents in patients with RA seen in everyday practice; they are not to be considered as a regulatory rule.

Publication types

  • Practice Guideline
  • Review
  • Systematic Review

MeSH terms

  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / therapy*
  • Biological Products / adverse effects
  • Biological Products / therapeutic use*
  • Biological Therapy / adverse effects
  • Biological Therapy / standards*
  • Evidence-Based Medicine / standards
  • Humans
  • Italy
  • Patient Selection
  • Rheumatology / standards*
  • Risk Assessment
  • Societies, Medical / standards*
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Biological Products